Keeping Track: Idorsia’s Quviviq Is FDA’s First Novel Approval Of 2022; AbbVie’s Rinvoq Gains Eczema Claim

 
• By Bridget Silverman
Keeping Track Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers